The newly established IGBA CEO Advisory Committee, a forum for generic and biosimilar medicines industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy matters, held its inaugural meeting on Monday, May 2 and launched initial discussions with World Trade Organization (WTO) Director-General Dr. Ngozi Okonjo-Iweala.
The International Generic and Biosimilar medicines Association (IGBA) announced today that it has established a CEO Advisory Committee composed of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States.
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
- GENEZIS, the Serbian and Montenegrin Generic and Biosimilar Medicines Association, joins IGBA (January 2022)
- Vivian Frittelli takes over the position of IGBA Chair (January 2022)
- IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access (November 2021)
- Global Biosimilars Week: Message of Sudarshan Jain, Chair, IGBA (October 2021)